U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07645651) titled 'Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer' on June 05.
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Resectable Pancreatic Ductal Adenocarcinoma
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma
Intervention:
DRUG: Samuraciclib
Given PO
PROCEDURE: Computed Tomography
Undergo CT
PROCEDURE: Endoscopic Ultrasound Biopsy
Undergo EU...